Rating Change
Barclays analysts reiterated a Overweight rating on 10x Genomics, Inc. (NASDAQ:TXG) on June 24, 2026.
reiterateNASDAQ:TXG
Barclays Reiterates Overweight Rating on 10x Genomics, Inc. (TXG)
Rating Change Barclays analysts reiterated a Overweight rating on 10x Genomics, Inc. (NASDAQ:TXG) on June 24, 2026. Market Context 10x Genomics, Inc.
Market Context
10x Genomics, Inc. operates in the Healthcare sector. The stock currently trades at $34.60 with a market capitalization of $2.0B.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for 10x Genomics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for 10x Genomics, Inc.
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 24, 2026 | Barclays | Overweight | N/A |
| May 12, 2026 | Morgan Stanley | Equal-Weight | N/A |
| May 12, 2026 | JP Morgan | Neutral | N/A |
| Apr 20, 2026 | B of A Securities | Neutral | N/A |
| Apr 20, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TXG Stock Page
Frequently Asked Questions
What does a Overweight rating mean for TXG?
A Overweight rating from Barclays reflects the analyst's outlook on 10x Genomics, Inc. (NASDAQ:TXG). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TXG forecast page.